A CDC analysis of 1,175 U.S. veterans aged 18 years or > from five Veterans Affairs Medical Centers found overall vaccine effectiveness against COVID-19–associated hospitalization to be 86.8% with similar effectiveness before (February 1–June 30) and after (July 1–August 6) Delta variant predominance. Effectiveness was 79.8% for patients 65 years or greater compared to 95.1% for patients 18 to 64 years.
A CDC analysis of data from 32,867 patient visits in nine states from June to August 2021 found overall effectiveness to be 86% at preventing hospitalizations. Effectiveness was 76% for patients 75 years or greater compared to 89% for patients 18 to 74 years. Vaccine effectiveness to prevent hospitalization was highest for the Moderna vaccine at 95% compared to 80% for the Pfizer-BioNTech vaccine and 60% for the J&J vaccine.
A CDC analysis of data from 569,142 viral infections in 13 states found a higher risk for COVID-19 infections, illness, and death in unvaccinated compared to vaccinated individuals.
Booster Vaccine Doses
In a 30-day, 940 patient, Phase III, CONCOR-1 trial (NCT04348656), treatment with convalescent plasma did not decrease intubation or death compared to standard of care (32.4% vs 28%) in patients with COVID-19 receiving oxygen within 12 days of respiratory symptom onset. Patients that received convalescent plasma experienced more adverse events than standard of care (33.4% versus 26.4%).
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker